By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Morria Biopharmaceuticals Plc 

53 Davies street

Mayfair  London  W1K5JH  United Kingdom
Phone: 44-0-207-152-6341 Fax: 44-0-207-152-6342


SEARCH JOBS


Industry
Biotechnology






Company News
Morria Biopharmaceuticals Plc Names Dr. Gur Roshwalb as CEO 3/5/2013 7:52:33 AM
Morria Biopharmaceuticals Plc Announces Quotation for Trading on the OTC Bulletin Board 2/19/2013 9:04:23 AM
Morria Biopharmaceuticals Plc Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer 1/23/2013 9:14:08 AM
Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board 7/18/2012 8:39:30 AM
Morria Biopharmaceuticals Plc Appoints Alan Harris, M.D., Ph.D., as Chief Medical Officer 7/2/2012 10:26:13 AM
Morria Biopharmaceuticals Plc Selects SCYNEXIS, Inc. to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis 2/16/2012 8:41:39 AM
Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress 6/15/2010 7:12:26 AM
Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress 6/3/2010 9:46:29 AM
Morria Biopharmaceuticals Plc Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 4/21/2010 9:21:55 AM
Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 8/25/2009 9:57:43 AM
123
//-->